FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Condition(s):Non-small Cell Lung Cancer (NSCLC)Last Updated:November 15, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Non-small Cell Lung Cancer (NSCLC)Last Updated:November 15, 2022Completed
Condition(s):Ventricular Tachycardia; Arrhythmia; Arrhythmic Storm; Radiation ToxicityLast Updated:December 21, 2023Enrolling by invitation
Condition(s):Non-small Cell Lung Cancer Stage ILast Updated:May 31, 2023Active, not recruiting
Condition(s):Renal Cell Carcinoma, Clear Cell, SomaticLast Updated:March 1, 2024Recruiting
Condition(s):Stage I Non-Small Cell Lung CancerLast Updated:July 3, 2023Active, not recruiting
Condition(s):Metastatic CancerLast Updated:June 29, 2023Active, not recruiting
Condition(s):Soft Tissue Sarcoma; Retroperitoneal Sarcoma; Radiotherapy Side Effect; Ultra-hypofractionated Radiotherapy; Stereotactic Ablative RadiotherapyLast Updated:February 4, 2022Recruiting
Condition(s):Prostate CancerLast Updated:August 25, 2022Completed
Condition(s):NSCLC, Stage ILast Updated:February 27, 2018Unknown status
Condition(s):Non-small Cell Lung Cancer; Oligoprogressive; Small-cell Lung CancerLast Updated:October 31, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.